ERp57 is an endoplasmic reticulum (ER) resident thiol disulfide oxidoreductase. Using the gene trap technique, we have created an ERp57-deficient mouse model. Targeted deletion of the Pdia3 gene, which encodes ERp57, in mice is embryonic lethal at embryonic day (E) 13.5. β-galactosidase reporter gene analysis revealed that ERp57 is expressed early on in blastocyst formation with the highest expression in the inner cell mass. In early stages of mouse embryonic development (E11.5) there was a relatively low level of expression of ERp57. As the embryos developed, ERp57 became highly expressed in both the brain and the lungs (E15.5 and E18.5). The absence of ERp57 had no impact on ER morphology; expression of ER associated chaperones and folding enzymes, ER stress, or apoptosis. ERp57 has been reported to interact with STAT3 (signal transducer and activator of transcription)-DNA complexes. We show here that STAT3-dependent signalling is increased in the absence of ERp57 and this can be rescued by expression of ER targeted ERp57 but not by cytoplasmic targeted protein, indicating that ERp57 affects STAT3 signalling from the lumen of the ER. ERp57 effects on STAT3 signalling are enhanced by ER luminal complex formation between ERp57 and calreticulin. In conclusion, we show that ERp57 deficiency in mouse is embryonic lethal at E13.5 and ERp57-dependent modulation of STAT3 signalling may contribute to this phenotype.
The endoplasmic reticulum (ER) # is involved in many cellular functions including protein synthesis and modification, regulation of Ca 2+ homeostasis, phospholipid and steroid synthesis, and regulation of the response to cellular stress (1) (2) (3) . To carry out these diverse functions, the ER is equipped with many chaperone proteins and folding enzymes (3) . For example, calreticulin, calnexin, and the oxidoreductase ERp57 are components of the folding machinery involved in the quality control of newly synthesized glycoproteins (3) . ERp57 forms complexes with calnexin and calreticulin to assist in chaperone functions to ensure that newly synthesized proteins are correctly folded (3) . Targeted deletion of ERp57 in B cells in mice results in normal B cell development and proliferation as well as antibody production (4) . However, there is aberrant assembly of the peptide loading complex indicating that ERp57 is involved in the assembly of the peptide loading complex and this protein contributes both qualitatively and quantitatively to major histocompatibility complex (MHC) class I antigen presentation in vivo (4) . Interestingly, small interfering RNA (siRNA) studies also demonstrate that ERp57 might be critical for oxidative folding of immunoglobulin heavy chain but not important for peptide loading of class I molecules (5) .
Aside from its role as a folding enzyme in quality control in the secretory pathway, ERp57, also known as glucose-regulated protein-58 or Grp58, (6) (7) (8) (9) (10) (11) (12) (13) has been reported to affect STAT3 (signal transducers and activators of transcription) signalling via interaction with STAT3 (6, (14) (15) (16) (17) . STATs are a family of cytoplasmic proteins with SH2 (Src Homology-2) domains that act as signal messengers and transcription factors as a part of the Janus kinase (JAK)-STAT pathway (18) . Upon activation, STAT proteins become phosphorylated on a specific tyrosine residue by activated JAK kinases and subsequently dimerize and translocate to the nucleus where they bind to specific DNA sequences to regulate the expression of target genes (18, 19) . Among the STAT proteins, STAT3 has been implicated in transduction of the cellular signals that are involved in the regulation of cardiac growth, development, and hypertrophy (20) . Although it is not clear how STAT3 activity is negatively regulated by ER resident ERp57, it has been reported that ERp57 may sequester the inactive and active STAT3 preventing its interaction with DNA and consequently activation of STAT3-dependent genes (6, 12) . TCAAGGCGAGTTACATGATCCC-3'; and INVR2 5'-CGAGCGTGACACCACGATGC-3'. Products of the inverse PCR-driven amplification were analyzed by agarose gel electrophoresis, purified using a gel purification kit (Qiagen), and sequenced. Once the integration site was identified, we designed a protocol for genotyping wild-type, heterozygote and homozygote ERp57-deficient embryos (Fig. 1 ). Embryos were harvested at embryonic days 10.5-15.5 followed by the isolation of genomic DNA. The following PCR primers were used for genotyping wild-type embryos: forward primer (F2) 5'-GGACAGTTTTGAGCTGCCAT-3' (hybridizes to the intron within the insertion of the vector site) and reverse primer (R3) 5'-TCTCCATTATCATCGTACTCC-3' (hybridizes to intron 4 after the vector insertion site). To identify heterozygous embryos the following primers were used: forward primer (F1)
5'-TCAAGGCGAGTTACATGATCCC-3' (hybridizes to the end of the inserted vector) and reverse primer R3.
Histological Analysis -Blastocysts were harvested at 3 days post-coitum and whole-mount β-galactosidase staining of blastocysts was performed. Blastocysts were washed with phosphate buffered saline (PBS), fixed in 3.7% paraformaldehyde in PBS for 30 min, then washed with PBS. Blastocysts were then incubated for 1 h in freshly prepared staining solution in 10 ml of PBS containing 2 mM MgCl 2 , 0.01% sodium deoxycholate, 0.02% NP40, and 0.1% 5-bromo-4-chloro-3-indoyl-β-Dgalactopyraonoside (X-gal) dissolved in dimethylformamide (24) . Photographs of blastocysts were taken using a Nikon Coolpix 995 camera attached to a Nikon eclipse TS100 microscope with a 10x magnification objective. β-galactosidase, hematoxylin, and eosin staining of wild-type and ERp57 +/-embryos was carried out as described previously (2) . β-galactosidase stained slides were counterstained with eosin (0.1% eosin in 0.1% acetic acid.). Embryos were viewed with the Nikon CoolscanIV.
Cell Culture, Plasmid DNA, DNA Cloning and Lentivirus Transduction -Mouse embryonic fibroblasts were isolated from day-11 wild-type and ERp57-deficient embryos, immortalized and maintained in culture as described previously (23) . When indicated, cells were treated with 1 μM thapsigargin or 2.5 μM brefeldin A for 16 hours.
cDNAs encoding full-length ERp57 or encoding mature ERp57 with no signal sequence were isolated from a mouse brain cDNA library using Gateway Cloning Technology (Invitrogen). The following forward DNA  primers were used for amplification of full length ERp57  and  no  signal  sequence  ERp57:  5'-GGGGACAAGTTTGTACAAAAAAGCAGGCTATAC  CATGCGCTTCAGCTGCCTAGCT-3' and 5'-GGGGACAAGTTTGTACAAAAAAGCAGGCTATAC CATGGATGTGTTGGAACTGACGGACGA -3', respectively. The forward primers contain an attB1 recombination site (bold), Kozak sequence for expression in mammalian cells (italics), and gene specific nucleotides (underlined). The same reverse primer was used for the synthesis of cDNAs encoding full-length and no signal sequence ERp57: 5'-GGGGACCACTTTGTACAAGAAAGCTGGGTCCT AGAGGTCTCTTGTGCCTTCTT-3'. The reverse primer contained an attB2 recombination site (bold) and the ERp57 gene specific nucleotides (underlined). Both forward and reverse primers required four guanine residues at the 5' end. First, a BP clonase reaction was carried out as recommended by the manufacturer to generate entry clone vectors. A recombination reaction was carried out using BP Clonase Enzyme Mix to insert cDNA encoding full-length ERp57 or no signal sequence ERp57 with the promoter EF1α (cellular polypeptide chain elongation factor 1 alpha) into the destination lentiviral vector 2K7 bsd (containing a blasticidine resistance gene for cell selection). Expression vectors p2K7ERp57 ER and p2K7ERp57 cyt contained cDNA encoding full-length ERp57 and no-signal sequence ERp57, respectively. Lentiviral transduction techniques were used to generate ERp57 -/-and wild-type fibroblast-derived cells lines stably expressing recombinant proteins ERp57 or no-signal sequence ERp57 (25) . Protein from bulk cell population was harvested with RIPA buffer containing 50 mM Tris, pH 7.5, 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1% Triton X-100, 0.1% SDS, 0.5% sodium deoxycholate, and protease inhibitors (0.5 mM phenylmethylsulfonyl fluoride [PMSF], 0.5 mM benzamidine, 0.05 µg/ml aproprotin, 0.025 µg/ml phosphormidone, 0.05 µg/ml Nα-tosyl-Lys-chloromethylketone [TLCK], 0.05 µg/ml 4-amidinophenyl)-methanesulfonyl fluoride hydrochloride monohydrate [APMSF], 0.05 µg/ml (2S,3S)-3-(Nf3dcarbamoyl)oxirane-2-carboxylic acid [E-64], 0.025 µg/ml leupeptin, and 0.01 µg/ml pepstatin) (26) . Expression of full-length ER targeted ERp57 and cytoplasmically targeted ERp57 (no signal sequence ERp57) was monitored by Western blot analysis (2, 25, 27) . ERp57-deficient cells expressing full-length ERp57 were denoted ERp57 -/--ERp57 ER and cells expressing no signal sequence-cytoplasmic ERp57 were denoted ERp57 -/--ERp57 cyt .
SDS-Polyacrylamide Gel Electrophoresis (PAGE) and Western Blot Analysis -Whole cell lysates from wild-type,

ERp57
-/-, ERp57 -/--57 ER and ERp57 -/--ERp57 cyt mouse embryonic fibroblasts were isolated as described previously (2) . Twenty µg of protein was separated by SDS-PAGE (10% acrylamide), transferred to nitrocellulose and probed with specific antibodies (28) . Antibodies used were rabbit-anti-Grp78/BiP at a dilution of 1:1000 (StressGen), rabbit-anti-calnexin at a dilution of 1:1000 (StressGen), goat-anti-calreticulin at a dilution of 1:300, rabbit-anti-ERp57 at a dilution of 1:1000, rabbitanti-protein disulfide isomerase (PDI) at a dilution of 1:1000, rabbit-anti-ERp41 at a dilution of 1:1000, rabbitanti-ERp54 at a dilution of 1:1000, and rabbit-anti-β-tubulin (Abcam) at a dilution of 1:1000 (2, 29) .
and
ERp57
-/--ERp57 cyt cells were grown to confluency and treated with 2 mM Na 3 VO 4 for 20 minutes prior to harvesting. Cells were washed with PBS containing 4 mM Na 3 VO 4 and harvested in RIPA buffer Thirty µg of protein was separated by SDS-PAGE (10% acrylamide) and transferred to nitrocellulose membrane (28) . The nitrocellulose membrane was washed with 25 ml of TBS buffer containing 20 mM Tris (pH 7.6), and 150 mM NaCl, and blocked for 1 h in TBS containing 5% milk and 0.1% Tween 20. Membranes were probed with rabbit-antiphospho-STAT3 (Y 705 ) antibodies (Cell Signalling) or anti-STAT3 (Cell Signalling) at 1:1000 dilutions overnight at 4°C. Secondary antibodies used were goatanti-rabbit (1:10,000 or 1:15,000 for anti-phospho-STAT3 antibodies) (Cell Signalling) and rabbit-anti-goat (1:10,000 for anti-STAT3 antibodies) (Cell Signalling). Blots were developed using a chemiluminescent system (28) . (26) . The cellular suspension was incubated on ice for 10 minutes then subjected to 40 strokes with a dounce homogenizer followed by a 20 min incubation on ice. The sample was centrifuged at 720 xg for 5 min and the supernatant containing cytoplasm, mitochondria and membranes was centrifuged at 10,000xg for 10 min. The supernatant containing cytoplasm and membranes was then subjected to a high speed centrifuge at 100,000 xg for 1 hour to separate the cytoplasmic fraction from the pellet containing ER-enriched membrane vesicles. Membrane pellet was suspended in 1 ml of RIPA buffer containing 50 mM Tris, pH 7.2, 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1% Tx-100, 0.1% SDS, 0.5% sodium deoxycholate, 200 μM PMSF, 100 μM benzamidine, and protease inhibitors (26) . Prior to SDS-PAGE proteins were precipitated with ice cold acetone. Proteins were transferred to nitrocellulose membrane followed by Western blot analysis with rabbit anti-ERp57 antibodies at a dilution of 1:1000.
Reverse Transcription (RT)-PCR -
FACS analysis -Samples were analyzed on BD FACScan single laser flow cytometry (BD Bioscience, San Diego) equipped with 488 nm filter. Data was collected from 10,000 cells and analyzed using CellQuest software. Cells at confluency of 80-90% were harvested by scraping into PBS, re-suspended in 100 μl of 0.1% formaldehyde in PBS and incubate for 30 min with rabbit anti-ERp57 antibodies at the concentration 1:150. Pelleted cells were than washed 3 times with PBS containing 2% FBS followed by addition of FITC label anti-rabbit (ALEXA Fluor 488 Invitrogen) secondary antibody. Cells were washed 3 times with PBS with FBS and once with PBS alone. Staining with secondary antibodies alone was used as a negative control. All experiments were carried out at least three times.
Luciferase Reporter Gene Assay -
, and crt -/--CRT E234R mouse embryonic fibroblasts was described previously (32) . ERp57 -/-and ERp57 -/--ERp57 ER cells were transfected with ER stress luciferase reporter vector [pRL-XFL, a generous gift from Dr. R.J. Kaufman (33)] as described previously (2) . Twenty four hours after transfection, cells were treated with thapsigargin (1 µM) or H 2 O 2 (50 µM) for 16 hours.
, and crt -/--CRT E234R cells were cotransfected with a luciferase reporter gene under control of the STAT3 promoter [pLucTKS3, a kind gift from Dr. J. Jung and was described previously (34, 35) ] with Renilla luciferase reporter at a 50:1 ratio, respectively (2). After 48 hours cells were harvested, lysed, and collected in Passive Lysis Buffer (Promega) followed by measurement of luciferase activity using the Dual-Luciferase Assay Kit (Promega) and a Berthold-Lumat 9507 luminometer (2) . Relative light units (RLUs) were normalized to the Renilla luciferase under the control of the Cytomegalovirus (CMV) promoter (2, 33) . Four independent transfection experiments were carried. Statistics were performed using two-sample unpaired t-tests were carried out.
Miscellaneous Procedures -Protein concentration was measured spectrophotometrically using a Bio-Rad procedure (2) . Ca 2+ fluorescence measurements were carried out using 0.5 µM Fura2-AM (22) . Cells were treated with 600 nM bradykinin and 300 nM thapsigargin (36) . Each trial was calibrated with 1 µM ionomycin and 4 mM CaCl 2 to obtain a maximum value and with 30 mM ethylene glycol tetraacetic acid (EGTA), 25 mM Tris-HCl, pH 7.4, and 0.4 % Triton X-100 to obtain a minimum value . Fluorescence was measured at λ ex =340 nm and λ ex =380 nm with λ em =510 nm. Ca 2+ concentrations were calculated from the fluorescence values. Figure 1A summarizes the results of the gene trapping strategy used to generate the ERp57-deficient mice. The Pdia3 gene, which encodes ERp57, was interrupted between introns 4 and 5 (nucleotides 14083-14084) with the pGT1.8TM cassette containing neomycin resistance and β-galactosidase genes (Fig. 1A) . PCR analysis of genomic DNA using the specific sets of primers depicted in Figure  1A allowed for determination of the genotypes of mice. Analysis of wild-type mice showed only a 797 base pair (bp) DNA product corresponding to the wild-type allele (Fig. 1B , primers F2 and R3) and no DNA product with primers F1 and R3 (Fig. 1B) . As expected, ERp57 -/-mice showed a 1800 bp DNA product with primers F2 and R3 and no product with primers F1 and R3 (Fig. 1B) . PCRdriven amplification of genomic DNA isolated from ERp57 +/-mice produced both the 797 bp and the 1800 bp DNA products, indicating the presence of one copy of the wild-type allele and one copy of the targeted knock-out allele (Fig. 1B) . Western blot analysis revealed that interruption of both alleles of the ERp57 gene resulted in no detectable expression of ERp57 protein (Fig. 1C) .
RESULTS
ERp57 Deficiency is Embryonic Lethal -
Chimeric mice were crossed with wild-type C57BL6 females to generate the first generation of heterozygotes.
ERp57
+/-B6/CD-1 mice were indistinguishable from wildtype animals. ERp57 +/-males were intercrossed to ERp57 +/-females to generate homozygote (ERp57 -/-) gene knockout mice. We were unable to obtain any viable
-/-pups from this cross. Viable embryos were obtained at E13 or earlier (Table 1) . Analysis of embryos at or after E13.5 showed a deficiency in the number of ERp57 -/-embryos indicating that a significant fraction of ERp57 -/-embryos died earlier than E13.5. We concluded that the ERp57 gene knockout was embryonic lethal and that ERp57 is essential for survival.
Developmental Activation of the ERp57
GeneHistological analysis of E12.5 ERp57 -/-embryos revealed that although there were no obvious gross morphological differences between ERp57 -/-and wild-type embryos, the ERp57 -/-embryos were markedly smaller than wild-type (Fig. 1D) . To gain additional insight into the potential role of ERp57 during embryonic development, we carried out β-galactosidase reporter gene analysis. The transgenic animals used in this study were generated by insertion of a gene cassette containing the β-galactosidase reporter gene (Fig. 1A) . To quantify transcriptional activation of the ERp57 gene we monitored expression of the β-galactosidase gene to evaluate ERp57 promoter activity in blastocysts and during embryonic development. Figure 2A shows high expression and activity of β-galactosidase in blastocysts 3 days post-coitum indicating high expression of ERp57 during the early stages of blastocyst formation. High activation of the ERp57 gene was confined to the inner cell mass ( Fig. 2A, icm) with relatively decreased activation of the gene in the blastocoel (Fig. 2A, b) and trophoblast ( Fig. 2A, t) . Next, ERp57 +/-and wild-type embryos were harvested at different gestational stages and stained for β-galactosidase activity. Activation of the ERp57 gene, as reported by high activity of β-galactosidase, was observed as early as E13.5 ( Fig. 2B) . At E13.5 there was high activation in the lung and vertebra but a relatively low activity of the gene in the liver and the heart (Fig. 2B) . At E15.5 β-galactosidase reporter gene activity was the highest in the lungs with elevated activation also observed in the liver, vertebra and intestine (Fig. 2C) . However, the activity was strikingly absent in the heart, thymus, and neurological tissue including the brain (Fig. 2C) . At the later stages of embryonic development (E18.5), the pattern of activation of the ERp57 gene significantly changed. Low activity of the ERp57 promoter was maintained in the heart, thymus, and skeletal muscle and high activity was observed in the lungs and liver (Fig. 2D) . At E18.5 we now observed a significant increase in the activation of the ERp57 gene in the brain which was absent in the E13.5 (Fig. 2D) . These data suggest that ERp57 may play a direct role during embryonic development, specifically in lung, liver, and vertebrae and, in the later developmental stages, in the brain. (Fig. 3A) . Figure  3B shows that wild-type and ERp57 -/--57 ER cells expressed ERp57 and that the protein was localized to an ER-like network. As expected, ERp57 was localized to the cytoplasmic compartment in ERp57-deficient cells expressing ERp57 without signal sequence (Fig. 3B ,
The ER in ERp57-
ERp57
-/--ERp57 cyt ). Cytoplasmic localization of ERp57 without signal sequence (ERp57 cyt ) was further confirmed by biochemical fractionation of ERp57-deficient cells expressing ERp57 without signal sequence (ERp57 -/--ERp57 cyt ) (Fig. 3C) . Finally, we carried out FACS analysis of different cells lines and showed that there was a small level of immunoreactive ERp57 detected on cell surface of cell lines used in this study (Fig. 3D) .
Morphologically, the ER appeared intact in all cell lines as judged by staining with Texas Red conjugated Concanavalin A, with antibodies raised against calreticulin and calnexin, or by electron microscopy analysis ( Fig. 3B  and E) . Western blot analysis demonstrated that there was no significant differences in the expression of ER chaperone proteins calreticulin, calnexin, Grp78/BiP, and Grp94 in the absence of ERp57 (Fig. 3F ). Next we examined the impact of the absence of ERp57 on other oxidoreductase folding enzymes family members. Again there was no significant change in expression of PDI and PDI-like family of protein ERp19 in the absence of ERp57 (Fig. 3F ). Slight increase in the level of ERp41 and decrease in the level of ERp54 was seen in the absence of ERp57 (Fig. 3F) . Thus, the absence of ERp57 had no major impact on the expression of other ER chaperones or folding enzymes. 4A) . In ERp57 -/-and ERp57 -/--ERp57 ER we observed a slight increase in Ca 2+ concentration in response to thapsigargin when compared to wild-type (Fig. 4B) , suggesting that there might be minor changes in ER Ca 2+ capacity in the absence of ERp57. This might be due to an ERp57-dependent regulation of SERCA2b activity (44) .
ER
The Unfolded Protein Response (UPR) in ERp57-deficient cells -Next, we examined if the absence of ERp57 led to any induction of ER stress and consequently the initiation of the UPR. The UPR was examined by splicing analysis of mRNA encoding X-box binding protein (Xbp1), which is cleaved and activated by ERstress-activated inositol-requiring enzyme (IRE)-1 (2). As a control, ER stress was induced using a classical ER stress inducer, thapsigargin (2) . In addition, we induced UPR/ER stress in wild-type and ERp57
-/-cells with brefeldin A (BFA), an ER-Golgi trafficking inhibitor (45) .
RT-PCR analysis was carried out to test for expression of Grp78/BiP mRNA and splicing of Xbp1, both markers of UPR. Non-stimulated wild-type and ERp57 -/-cells did not have an increased level of Grp78/BiP mRNA nor was there any observable splicing of Xbp1 mRNA (Fig. 5A) . As expected, thapsigargin induced complete splicing of Xbp1 (Fig. 5A, Xbp1s) as well as a significant increase in the level of Grp78/BiP mRNA (Fig. 5A) . When wild-type and ERp57
-/-cells were treated with BFA, there was incomplete splicing of Xbp1 with both unspliced (Fig. 5A , Xbp1us) and spliced (Fig. 5A, Xbp1s) forms of Xbp1 mRNA detected. Interestingly, both the level of Grp78/BiP mRNA and the spliced form of Xbp1 were increased in ERp57 -/-compared to wild-type cells (Fig.  5A) , indicating that ERp57 -/-cells were more sensitive to BFA-induced ER stress.
Next, we quantified Xbp1 splicing using a luciferase reporter system developed by Kaufman's group (33) . In this system, only the spliced form of the Xbp1 is in frame with the luciferase reporter gene, therefore, high luciferase activity reports splicing of Xbp1 and increased ER stress (33) . Figure 5B shows that there was a small but significant increase in the UPR in ERp57 -/-cells when compared to wild-type cells (Fig. 5B) and this was not rescued by expression of the recombinant ERp57 (Fig.  5B) . Thapsigargin treatment significantly enhanced luciferase activity in wild-type, ERp57
-/-and ERp57 -/--ERp57 ER cells (Fig. 5B) . There was an 8-fold increase in UPR activation upon treatment with thapsigargin when compared to non-stimulated counterparts (Fig. 5B) . (Fig.  5C ). We concluded that ERp57 deficiency did not have a significant effect on ER morphology; expression of ER associated chaperones and folding enzymes, ER stress, or apoptosis.
STAT3 Activation in the Absence of ERp57 -Earlier reports indicate that ERp57
, in addition to its function as an ER oxidoreductase folding enzyme, may play a role in modulation of the STAT3 signalling (6, 15, 48) . It has been proposed that ERp57 forms complexes with both inactive and active STAT3, preventing STAT3 interaction with DNA and consequently leading to inhibition of STAT3-dependent signalling pathway (6, 48) . Therefore we took advantage of ERp57-deficient cells and examined whether the absence of ERp57 affected STAT3 signalling. STAT3 signalling was monitored using RT-PCR, Western blot analyses of inactive and active (phosphorylated-Y 705 ) STAT3, and luciferase activity assay for STAT3 activated promoter. Figure 6A shows that expression of STAT3 mRNA was not affected in the absence of ERp57 (ERp57 -/-) nor in ERp57-deficient cells transfected with ERp57 expression vector encoding ERp57 localized to the ER (ERp57 -/--ERp57 ER ). Tubulin expression was measured as a control. However, Western blot analysis showed increased levels of STAT3 protein and phospho-STAT3 (Y 705 ) (Fig. 6B ). The level of phospho-STAT3 was not changed in ERp57
-/--ERp57 cyt (Fig. 6B) . To quantify STAT3 activation we used plucTKS3 plasmid DNA containing firefly luciferase reporter gene under the control of STAT3 binding sites (34) . Since ERp57 has been shown to inhibit STAT3 activity, we expected that STAT3-dependent activation of the promoter would result in high activity of luciferase in the absence of ERp57.
Wild-type, ERp57
-/-, ERp57-deficient cells expression ER target ERp57 (ERp57 -/--ERp57 ER ), cytoplasm target ERp57 (no N-terminal signal sequence, ERp57 -/--ERp57 cyt ) and green fluorescent protein (GFP) control were transfected with luciferase reporter plasmid followed by analysis of luciferase activity. In non-stimulated ERp57 -/-cells, there was 2-fold increase in STAT3 activation (Fig.  6C) indicating that there was a link between ERp57 and STAT3 activity. Since STAT3 is a cytoplasmic/nuclear transcription factor found in the cytoplasm, for ERp57 to interact directly with STAT3 to form functional complexes, ERp57 would have to be also present in the cytoplasm. Therefore, we tested if the ER targeted or cytoplasm targeted ERp57 was effective in modulation of STAT3 signalling. High activity of STAT3 in ERp57 -/-cells was partially rescued in ERp57-deficient cells expressing ER targeted ERp57 (Fig. 6C, ERp57 -/--ERp57 ER ) but not in ERp57 -/-cells expressing cytoplasm targeted protein (Fig. 6C, ERp57 -/--ERp57 cyt ). As expected, expression of the recombinant GFP in ERp57-deficient cells did not have any effect on STAT3 transcriptional activity. Figure 3D shows that there was a detectable level of immunoreactive ERp57 at the cell surface. However, we do not believe that this small fraction of ERp57 contributes to the modulation of STAT3 transcriptional activity since addition of purified ERp57 to cell cultures did not affect STAT3 transcriptional activity in the ERp57-deficient cells (Supplementary Figure 1) . We concluded that the ER targeted ERp57 was the most effective in influencing STAT3 signalling, suggesting that ERp57 modulates STAT3 activity from the lumen of the ER.
Calreticulin Enhances ERp57 Modulation of STAT3
Signalling -ERp57 forms functional complexes with calreticulin to assist in folding and posttranslational modification of newly synthesized proteins (3). We asked whether calreticulin may influence ERp57-dependent STAT3 activity. To do this we employed crt -/-cells lines expressing wild-type calreticulin or calreticulin mutants defective in binding ERp57 (32) . In this study we used a loss of ERp57 binding calreticulin-E 239 R mutant and a calreticulin-G 242 A mutant that has no loss in ERp57 binding (32) . Western blot analysis showed that STAT3 or phospho-STAT3 (Y 706 ) expression was not affected by expression of calreticulin or calreticulin mutants in crt -/-cells (Fig. 7) . Surprisingly, quantitative analysis of STAT3 activity using luciferase reporter gene system showed high activity of STAT3 in crt -/-cells compared to wild-type counterparts (Fig. 7B) , indicating that calreticulin may also affect STAT3 signalling. Figure 7B shows that STAT3 was not affected in the absence of calnexin, a homologue of calreticulin. Expression of wild-type calreticulin (Fig. 7B, crt -/--CRT) or a calreticulin mutant interacting with ERp57 (Fig. 7B, crt -/--CRT
G242A
) resulted in full recovery of STAT3 activity back to the level observed in wild-type cells (Fig. 7B, wt) . In contrast, expression of calreticulin mutant with a loss of ERp57 binding had no effect on STAT3 activity (Fig. 7B, crt -/--CRT E239R ), which remained high and at the same level as observed in calreticulin deficient cells (Fig. 7B, crt -/-). Taken together, these results indicate that ERp57-dependent modulation of STAT3 from the lumen of the ER requires calreticulin capable of forming complexes with ERp57.
DISCUSSION
In this study, we showed that deletion of the Pdia3 gene, which encodes ERp57, was embryonic lethal at E13.5. Biochemical and cell biological analysis of ERp57-deficient cells indicated that the absence of ERp57 has no impact on ER morphology, expression of ER associated chaperones and folding enzymes, ER stress, or apoptosis. However, we show that STAT3-dependent signalling was increased in the absence of ERp57 and this could be rescued by expression of the ER targeted ERp57, indicating that ERp57 affects STAT3 signalling from the lumen of the ER. This effect of ERp57 on the STAT3 pathway is further enhanced by an ER luminal complex formation between ERp57 and calreticulin. Increased STAT3 activity in the absence of ERp57 may contribute to embryonic lethality of ERp57 -/-mice. The ERp57 gene is differentially regulated during embryonic development indicating that the protein may play a direct role in the development of specific tissues. This is in line with earlier observations of the expression of ER associated ERp57 partner proteins, calreticulin and calnexin (2, 23) . Calreticulin is predominately expressed in the heart during early stages of embryonic development and calreticulin-deficient mice die at E14.5 from impaired cardiac development (23) . In contrast the calnexin gene is highly activated in neuronal tissue (2) and calnexindeficient mice are born with neurological abnormalities (49) . In this study, we showed that the ERp57 gene was highly active in the inner cell mass of blastocysts, an origin of the fetus formation (50) and in the lung, liver, and brain during early stages of embryogenesis, suggesting that impaired development of these tissues may, at least in part, contribute to ERp57 -/-embryonic lethality. The high expression of ERp57 in the lungs seen in this study is of interest because it has recently been reported that ERp57 is decreased in a neonatal rat model of hyperoxia-induced lung injury and cultured cells (47) . siRNA knockdown of ERp57 in human endothelial cells resulted in cellular protection against hyperoxia and tunicamycin-induced caspase-3 activation apoptosis, suggesting that ERp57 has a role in the regulation of apoptosis (47) . Garbi et al. (4) carried out a targeted deletion of the ERp57 gene in mouse B cells. They also reported no ERp57 -/-offspring, indicating that an ERp57 deficiency might be embryonic lethal. Here we investigated embryonic development in the absence of ERp57 and showed that ERp57 -/-was embryonic lethal at E13.5. Interestingly, deletion of ERp57 in B cells in mice results in normal B cell development, proliferation, and antibody production indicating that ERp57 is not required for glycoprotein folding in B cells (4) . However, there is aberrant assembly of the peptide loading complex, showing that ERp57 is involved in the assembly of the peptide loading complex and it contributes both qualitatively and quantitatively to MHC class I antigen presentation in vivo. This supports earlier observations that ERp57 is critically involved in the early folding events of MHC class I heavy chain (5, 14) . The role of ERp57 in MHC class I biogenesis and assembly is further supported by ERp57 siRNA studies (5, 51, 52) .
In addition to its role as a folding enzyme in quality control in the secretory pathway, ERp57 is reported to affect STAT3 signalling (12) . This may be due to formation of inhibitory complexes between ERp57 and STAT3 protein either in the cytoplasm or the nucleus (6, 15, 48, 53, 54) . Furthermore, in avian and mammalian cells, DNA-protein cross-linking experiments indicate that ERp57 is nuclear and it interacts directly with DNA (15) . In vitro experiments in HeLa cells showed that ERp57 preferentially binds DNA sequences having characteristic scaffold/matrix associated regions (S/MARs) (55) . Finally, the protein has also been suggested to be present on the cell surface and in the cytoplasm (6, (14) (15) (16) (17) . Using FACS analysis we detected some immunoreactive ERp57 on the surface of cells used in this study. However, it is unlikely that the cell surface ERp57 affects STAT3 transcriptional activity as addition of extracellular ERp57 did not affected STAT3 function (Supplementary Figure 1) . The conundrum is then: how does ERp57 gain access to the cytoplasm/nucleus to influence STAT3 activity when its N-terminal signal sequence should direct it to the ER and its C-terminal QDEL ER retrieval motif should keep it there? To address this question, we took advantage of available ERp57-deficient cells and tested, for the first time, STAT3 signalling in the absence of ERp57. Analysis of STAT3-dependent expression of the luciferase reporter gene in ERp57-deficient cells revealed that ERp57 indeed affects STAT3 signalling. Most importantly, we showed that the ER but not the cytoplasmic form of ERp57 was effective in inhibition of STAT3 activity. This effect is specific to ERp57, since transfection of ER targeted GFP or calnexin did not have any effect on the STAT3 activity. Figure 8 shows a model of ERp57 function in the lumen of the ER. ERp57 is an ER resident folding enzyme involved in oxidative folding of glycoproteins in the ER, biosynthesis of the MHC class I, and as a component of the loading complex (14) . In this study, we showed that ERp57 also affects STAT3 signalling from the lumen of the ER (Fig. 8) . It is not clear at present how ERp57 affected STAT3 signalling, but our work indicates that the inhibitory function of ERp57 was significantly enhanced by interaction with another ER resident luminal protein, calreticulin (Fig. 8) . The two proteins form functional complexes involved in folding and posttranslational modification of newly synthesized (glyco)proteins (42) . Our results indicate that ERp57-dependent modulation of STAT3 activity also depends on the formation of ERp57-calreticulin complexes in the lumen of the ER.
Interestingly, ERp57-calreticulin complex formation might also be important for cell surface targeting of these ER proteins (56) .
The molecular mechanisms of ERp57-dependent signalling from the ER are not presently clear, however, several other cellular processes are controlled by "ER signalling". For example, cholesterol homeostasis is controlled by ER-nuclear signalling via sterol-regulated proteolysis of ER membrane bound transcription factors called sterol regulatory element-binding proteins (57) . The UPR is also regulated by ER associated kinases which transduce their signals from the ER to affect gene expression in the nucleus (58) . One critical aspect of Ca 2+ homeostasis is involved in store-operated Ca 2+ influx resulting from ER-dependent activation of the plasma membrane Ca 2+ channel (59) . Transcriptional activity of steroid receptors is also modulated by ER luminal proteins (60). Here we report, for the first time, that the STAT3-dependent pathway may also be modulated by signalling from the ER. 
-/--ERp57 cyt , ERp57-deficient cells expressing cytoplasmic targeted ERp57; FACS, fluorescence-activated cell sorting; FITC, fluorescein isothiocyanate; GAPDH, glyceraldehyde 3-phosphate dehydrogenase; MHC, major histocompatibility complex; PBS, phosphate-buffered saline; PCR, polymerase chain reaction; PDI, protein disulfide isomerase; RT, reverse transcription; SDS-PAGE, sodium dodecyl sulfate polyacrylamide gel electrophoresis; SERCA, sarcoplasmic/endoplasmic reticulum Ca 2+ ATPase; STAT, signal transducers and activators of transcription; UPR, unfolded protein responses; Xbp, X-box binding protein. -/-embryos. Primers R3 and F1 were used for detection of wild-type alleles and R3 and F2 for mutated allele. C. Western blot analysis with anti-ERp57 antibodies (upper panel). Lower protein band corresponds to a nonspecific immunoreactivity. Anti-glyceraldehyde 3-phosphate dehydrogenase (GAPDH) antibodies were used to normalize for protein loading (lower panel). D. Hematoxylin and Eosin staining of embryonic day 12.5 wild-type (wt) and ERp57-deficient embryos (ERp57 -/-).
FIGURE 2. Activation of the ERp57 promoter during mouse embryogenesis.
Expression of the ERp57 gene was detected as β-galactosidase activity from the β-galactosidase reporter gene inserted in the ERp57 gene within the ERp57 +/-mouse (see Figure 1) . A. Activation of the ERp57 promoter in mouse blastocysts. High activation of the ERp57 gene was detected in the inner cell mass (icm) of the blastocysts but not in the blastocoels (b) or the trophoblasts (t). B. Activation of the ERp57 promoter in lung, liver, and spine but not the heart of E13. 
